Results 21 to 30 of about 20,619 (221)

Insulin Like Growth Factor Binding Protein 7 as a Novel Diagnostic Marker in Sera of Iraqi Patients with Acromegaly

open access: yesمجلة بغداد للعلوم, 2023
The purpose of this study was to measure serum levels of insulin-like growth factor-binding protein (IGFBP7), Insulin-like Growth Factor 1 (IGF-1), Growth Hormone (GH), Interleukin 6 (IL-6) and insulin in acromegaly patients and healthy controls.
Layla Othman Farhan   +3 more
doaj   +1 more source

Skeletal complications in acromegaly

open access: yes, 2023
Hypersecretion of growth hormone (GH) is rare and typically results from a pituitary functional tumor – somatotropinoma. It leads to excessive linear bone growth and manifests as gigantism if occurring in childhood and adolescence, before the closure of ...
Arnika Wydra   +2 more
core   +1 more source

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation [PDF]

open access: yes, 2009
Background: Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1).
Martin J Connock   +18 more
core   +1 more source

Acromegaly [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2008
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The prevalence is estimated at 1:140,000-250,000.
Chanson Philippe, Salenave Sylvie
openaire   +3 more sources

Acromegaly [PDF]

open access: yesThe American Journal of the Medical Sciences, 1897
n ...
openaire   +4 more sources

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice

open access: yesBMC Endocrine Disorders, 2020
Background Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint pain,
Eliza B. Geer   +8 more
doaj   +1 more source

CONDITION OF THE MUSCULOSKELETAL SYSTEM IN PATIENTSWITH ACROMEGALY.

open access: yesОстеопороз и остеопатии, 2010
Despite the relatively low incidence of acromegaly (60-70 cases per I million inhabitants), this disease has a special place among the heterogeneous group of diseases that lead to the defeat of the locomotor apparatus.
A S Fedotova   +7 more
doaj   +1 more source

Acromegaly Presenting With Cricoarytenoid Joint Arthropathy. [PDF]

open access: yesLaryngoscope
Excess growth hormone in acromegaly induces characteristic acral and soft tissue overgrowth (particularly in the face and hands), arthropathies, as well as cardiovascular and metabolic complications. Similar proliferative changes can occur in the larynx, where hypertrophy of the arytenoid and cricoid cartilages may impair vocal fold mobility.
Salvi Cruz S   +3 more
europepmc   +2 more sources

ACROMEGALY [PDF]

open access: yesThe Journal of Nervous and Mental Disease, 1892
n ...
openaire   +5 more sources

Acromegaly presenting with myelopathy due to ossification of posterior longitudinal ligament: a case report

open access: yesBMC Musculoskeletal Disorders, 2021
Background Acromegaly is a rare disease caused by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), often originating from a pituitary adenoma.
Daisuke Kamakura   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy